UPB
NASDAQUpstream Bio Inc.
News25/Ratings10
Price$2.75-0.57 (-17.19%)
01:30 PM07:45 PM
News · 26 weeks35-100%
2026-04-192026-10-11
Mix1390d
- Other5(38%)
- Insider5(38%)
- SEC Filings3(23%)
Latest news
25 items- INSIDERGeneral Counsel Ambrose Allison sold $2,663 worth of shares (485 units at $5.49), decreasing direct ownership by 3% to 15,563 units (SEC Form 4) to satisfy withholding tax4 - Upstream Bio, Inc. (0002022626) (Issuer)
- INSIDERCFO and COO Gray Michael sold $4,683 worth of shares (853 units at $5.49), decreasing direct ownership by 3% to 27,942 units (SEC Form 4) to satisfy withholding obligation4 - Upstream Bio, Inc. (0002022626) (Issuer)
- INSIDERChief Medical Officer Deykin Aaron sold $4,914 worth of shares (895 units at $5.49), decreasing direct ownership by 3% to 32,302 units (SEC Form 4) (for withholding tax)4 - Upstream Bio, Inc. (0002022626) (Issuer)
- INSIDERChief Business Officer Houghton Adam sold $3,843 worth of shares (700 units at $5.49), decreasing direct ownership by 3% to 22,901 units (SEC Form 4) (withholding tax)4 - Upstream Bio, Inc. (0002022626) (Issuer)
- INSIDERChief Executive Officer Sutherland Everett Rand sold $11,502 worth of shares (2,095 units at $5.49), decreasing direct ownership by 3% to 68,717 units (SEC Form 4) (withholding obligation)4 - Upstream Bio, Inc. (0002022626) (Issuer)
- PRUpstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026– Verekitug, 100 mg dosed every 12 weeks, reduced AAER by 56% compared to placebo in patients with severe asthma – – Verekitug also delivered clinically meaningful improvements in lung function (FEV1) and exhaled nitric oxide (FeNO) with every 12-week dosing – – The Company remains on track to initiate Phase 3 trials in severe asthma and CRSwNP in Q1 2027, designed to deliver best-in-class efficacy in both indications by evaluating a 400 mg quarterly regimen of verekitug in broad patient populations – WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for severe inflammatory respiratory diseases, today prese
- SECUpstream Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Upstream Bio, Inc. (0002022626) (Filer)
- PRUpstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP– Following productive FDA discussions, Upstream Bio will study 400 mg of verekitug administered every 12 weeks, versus placebo, in severe asthma and CRSwNP with one pivotal Phase 3 trial in each indication – – The Company’s Phase 3 strategy is designed to deliver best-in-class efficacy across both indications by evaluating a high-dose, quarterly regimen of verekitug in broad patient populations – – The Company remains on track to initiate both Phase 3 trials in Q1 2027 – WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for severe inflammatory respiratory diseases, today announced its pivotal Phase 3 devel
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Upstream Bio Inc.SCHEDULE 13G/A - Upstream Bio, Inc. (0002022626) (Subject)
- SECSEC Form 10-Q filed by Upstream Bio Inc.10-Q - Upstream Bio, Inc. (0002022626) (Filer)
- SECUpstream Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Upstream Bio, Inc. (0002022626) (Filer)
- PRUpstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress– Company rapidly advancing toward Q1 2027 initiation of Phase 3 trials designed to deliver best-in-class efficacy with convenient quarterly dosing in both severe asthma and CRSwNP; End-of-Phase 2 interactions with FDA on track – – Completed enrollment in Phase 2 trial in COPD; data expected in the second half of 2027 – – Clinical data presentations continue to emphasize differentiated profile of verekitug in multiple indications – WALTHAM, Mass., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for severe inflammatory respiratory diseases, today reported financial results and business updates for the second quarter ended
- SECSEC Form SCHEDULE 13G filed by Upstream Bio Inc.SCHEDULE 13G - Upstream Bio, Inc. (0002022626) (Subject)
- INSIDERChief Business Officer Houghton Adam sold $4,270 worth of shares (700 units at $6.10), decreasing direct ownership by 3% to 23,601 units (SEC Form 4) (for withholding tax)4 - Upstream Bio, Inc. (0002022626) (Issuer)
- INSIDERCFO and COO Gray Michael sold $5,203 worth of shares (853 units at $6.10), decreasing direct ownership by 3% to 28,795 units (SEC Form 4) to satisfy withholding obligation4 - Upstream Bio, Inc. (0002022626) (Issuer)
- INSIDERChief Executive Officer Sutherland Everett Rand sold $12,780 worth of shares (2,095 units at $6.10), decreasing direct ownership by 3% to 70,812 units (SEC Form 4) to satisfy withholding obligation4 - Upstream Bio, Inc. (0002022626) (Issuer)
- INSIDERChief Medical Officer Deykin Aaron sold $5,460 worth of shares (895 units at $6.10), decreasing direct ownership by 3% to 33,197 units (SEC Form 4) (for withholding tax)4 - Upstream Bio, Inc. (0002022626) (Issuer)
- INSIDERGeneral Counsel Ambrose Allison sold $2,910 worth of shares (477 units at $6.10), decreasing direct ownership by 3% to 16,048 units (SEC Form 4) to satisfy withholding tax4 - Upstream Bio, Inc. (0002022626) (Issuer)
- PRUpstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants – – Majority of verekitug-treated participants experienced clinically meaningful improvements across key secondary endpoints, including 72% in nasal congestion and 83% in CRSwNP total symptom score – WALTHAM, Mass., June 14, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today presented new responder analyses from the Phase 2 VIBRANT trial of verekitug in participants with chronic rhinosinusitis
- ANALYSTUpstream Bio downgraded by Analyst with a new price targetAnalyst downgraded Upstream Bio from Overweight to Neutral and set a new price target of $8.00
- INSIDERSEC Form 4 filed by Director Beckman Daniella4 - Upstream Bio, Inc. (0002022626) (Issuer)
- INSIDERSEC Form 4 filed by Director Ratcliffe Liam4 - Upstream Bio, Inc. (0002022626) (Issuer)
- INSIDERSEC Form 4 filed by Director Renaud Ronald C Jr4 - Upstream Bio, Inc. (0002022626) (Issuer)
- INSIDERSEC Form 4 filed by Director Fleming Harold Edward4 - Upstream Bio, Inc. (0002022626) (Issuer)
- INSIDERSEC Form 4 filed by Director Ruddy Marcella K.4 - Upstream Bio, Inc. (0002022626) (Issuer)
UPB FAQ
6 questionsWhere does UPB stock trade?
Upstream Bio Inc. (UPB) is listed on NASDAQ.What sector and industry is UPB in?
Upstream Bio Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Upstream Bio Inc. go public?
Upstream Bio Inc. (UPB) completed its IPO in 2024.What are analysts saying about UPB?
Upstream Bio Inc. has had 8 recent analyst actions on file. The most recent action was from Analyst: Neutral with a $800.00 price target on 2026-06-12.What companies are similar to UPB?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare UPB side-by-side with any of them on Quantisnow.How can I track UPB on Quantisnow?
Quantisnow aggregates Upstream Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow UPB to receive live email and push alerts on every new disclosure.